Severe Influenza Cohort

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

227 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-16

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Influenza is a major cause of morbidity and mortality. The investigators first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Asymptomatic Flu Project

NCT02868658

Influenza

COMPLETED NA

Novel Influenza A (H1N1) Surveillance Registry

NCT01046331

Novel Influenza A H1N1 Influenza

COMPLETED

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

NCT03020537

Influenza

COMPLETED PHASE4

Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years

NCT01289535

Immune Response

UNKNOWN PHASE4

Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients

NCT01022905

HIV Infection Rheumatic Disease Cancer +2 more

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Severe Respiratory Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

influenza cohort

Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation.

1 control group of 30 patients (ancillary study) will be constitued to have reference values of the HLA-G5 marker.

Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Group Type OTHER

influenza cohort

Intervention Type OTHER

Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

influenza cohort

Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient (Adult or Pediatric)
* Hospitalized in reanimation
* With a laboratory confirmed Influenza
* That agree to take part in the study
* Affiliated to National Health Insurance

For ancillary group :

* Adult at least 60 years old
* Presenting at hospital for a blood test

Exclusion Criteria

* non willing to participate
* Influenza infection with no respiratory symptoms
* pregnancy

For ancillary group :

* Presence of immunodepression defined by:

* Cancer, or cancer cured for less than 2 years
* Corticosteroids, Methotrexate (MTX), anti Tumor Necrosis Factor (TNF), anti-CD20
* Infection in progress (fever)

Minimum Eligible Age

1 Month

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No